317 related articles for article (PubMed ID: 32240649)
21. Biomarkers for severe allergic asthma in children: could they be useful to guide disease control and use of omalizumab?
Amat F; Labbé A
Expert Rev Respir Med; 2018 Jun; 12(6):475-482. PubMed ID: 29741411
[TBL] [Abstract][Full Text] [Related]
22. Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review.
Colombo GL; Di Matteo S; Martinotti C; Oselin M; Valentino MC; Bruno GM; Pitotti C; Menzella F
Ther Adv Respir Dis; 2019; 13():1753466619841350. PubMed ID: 31035904
[TBL] [Abstract][Full Text] [Related]
23. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
Hanania NA; Alpan O; Hamilos DL; Condemi JJ; Reyes-Rivera I; Zhu J; Rosen KE; Eisner MD; Wong DA; Busse W
Ann Intern Med; 2011 May; 154(9):573-82. PubMed ID: 21536936
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review.
Corren J; Kavati A; Ortiz B; Colby JA; Ruiz K; Maiese BA; Cadarette SM; Panettieri RA
Allergy Asthma Proc; 2017 Jul; 38(4):250-263. PubMed ID: 28631599
[TBL] [Abstract][Full Text] [Related]
25. 'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.
Abraham I; Alhossan A; Lee CS; Kutbi H; MacDonald K
Allergy; 2016 May; 71(5):593-610. PubMed ID: 26644231
[TBL] [Abstract][Full Text] [Related]
26. Omalizumab may decrease the thickness of the reticular basement membrane and fibronectin deposit in the bronchial mucosa of severe allergic asthmatics.
Zastrzeżyńska W; Przybyszowski M; Bazan-Socha S; Gawlewicz-Mroczka A; Sadowski P; Okoń K; Jakieła B; Plutecka H; Ćmiel A; Sładek K; Musiał J; Soja J
J Asthma; 2020 May; 57(5):468-477. PubMed ID: 30905217
[No Abstract] [Full Text] [Related]
27. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study.
Casale TB; Luskin AT; Busse W; Zeiger RS; Trzaskoma B; Yang M; Griffin NM; Chipps BE
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):156-164.e1. PubMed ID: 29800752
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study.
Chen HC; Huang CD; Chang E; Kuo HP
BMC Pulm Med; 2016 Jan; 16():3. PubMed ID: 26747278
[TBL] [Abstract][Full Text] [Related]
29. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
Özgür ES; Özge C; Ïlvan A; Naycı SA
J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
[TBL] [Abstract][Full Text] [Related]
30. Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics' responsiveness to omalizumab.
Suzukawa M; Matsumoto H; Ohshima N; Tashimo H; Asari I; Tajiri T; Niimi A; Nagase H; Matsui H; Kobayashi N; Shoji S; Ohta K
Respir Med; 2018 Jan; 134():95-102. PubMed ID: 29413515
[TBL] [Abstract][Full Text] [Related]
31. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
[TBL] [Abstract][Full Text] [Related]
32. Obesity influences the outcomes of anti-IgE (omalizumab) therapy of asthma.
Gu C; Upchurch K; Mamaril-Davis J; Wiest M; Lanier B; Millard M; Turner J; Joo H; Oh S
Clin Exp Allergy; 2020 Oct; 50(10):1196-1199. PubMed ID: 32585057
[No Abstract] [Full Text] [Related]
33. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.
Riccio AM; Dal Negro RW; Micheletto C; De Ferrari L; Folli C; Chiappori A; Canonica GW
Int J Immunopathol Pharmacol; 2012; 25(2):475-84. PubMed ID: 22697079
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab.
Pereira Santos MC; Campos Melo A; Caetano A; Caiado J; Mendes A; Pereira Barbosa M; Branco Ferreira M
Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):38-40. PubMed ID: 25781192
[TBL] [Abstract][Full Text] [Related]
35. Omalizumab: a review of its use in the treatment of allergic asthma.
Plosker GL; Keam SJ
BioDrugs; 2008; 22(3):189-204. PubMed ID: 18481901
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States.
Sullivan PW; Li Q; Bilir SP; Dang J; Kavati A; Yang M; Rajput Y
Curr Med Res Opin; 2020 Jan; 36(1):23-32. PubMed ID: 31491337
[No Abstract] [Full Text] [Related]
37. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
[TBL] [Abstract][Full Text] [Related]
38. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.
Chipps BE; Zeiger RS; Luskin AT; Busse WW; Trzaskoma BL; Antonova EN; Pazwash H; Limb SL; Solari PG; Griffin NM; Casale TB
Ann Allergy Asthma Immunol; 2017 Dec; 119(6):524-532.e2. PubMed ID: 29054589
[TBL] [Abstract][Full Text] [Related]
39. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma.
Takaku Y; Soma T; Nishihara F; Nakagome K; Kobayashi T; Hagiwara K; Kanazawa M; Nagata M
Int Arch Allergy Immunol; 2013; 161 Suppl 2():107-17. PubMed ID: 23711861
[TBL] [Abstract][Full Text] [Related]
40. A review of omalizumab for the management of severe asthma.
Lin CH; Cheng SL
Drug Des Devel Ther; 2016; 10():2369-78. PubMed ID: 27528798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
